ArticleOncotarget2016

Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer.

Yun Ling et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.